Targeted radionuclide treatment achieves high response rate, minimal toxicities for advanced-stage neuroendocrine tumors
A targeted radionuclide alpha therapy, 225Ac-DOTATATE, has been shown to have long-term anti-tumor effects in patients with advanced-stage gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Results from the Phase II ...
Jun 15, 2022
0
2